Yazar "Issever, Halim" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Combined effect of parathyroid hormone and strontium ranelate on bone healing in ovariectomized rats
    (WILEY, 2018) Goker, Funda; Ersanli, Selim; Arisan, Volkan; Cevher, Erdal; Guzel, Emine Elif; Issever, Halim; Omer, Beyhan; Altun, Gulay Durmus; Morina, Deniz; Yilmaz, Tugba Ekiz; Dervisoglu, Elmire; Del Fabbro, Massimo
    ObjectiveParathyroid hormone (PTH) enhances bone healing. Strontium ranelate (SR) is an antiresorptive agent that increases bone formation. Reports about combined effects of PTH and SR on local bone regeneration in osteoporotic subjects are limited. We aimed at investigating the efficacy of PTH and SR for promoting new bone formation in critical-sized defects of ovariectomized rats. Materials and MethodsParathyroid hormone- and/or SR-containing poloxamer implant tablets with/without chitosan microparticles were delivered locally to calvarial defects of 90 Wistar rats. Biopsies were analyzed histologically and histomorphometrically at 4 and 8weeks of healing. ResultsHistomorphometry revealed that PTH alone promoted new bone formation at 4weeks but the efficiency declined in 8weeks. There was no positive effect of SR alone on bone formation at 4 or 8weeks. Calvarial defects treated with PTH+SR combinations showed statistically significant greater new bone formation than either treatment alone at both time intervals. Tissue responses were modest and supported the good biocompatibility of the biomaterials used. ConclusionParathyroid hormone and SR combinations can be effective for calvarial bone regeneration of ovariectomized rats. PTH plus SR may have potential use as bone graft material in orthopedic and dental surgery to enhance bone healing and osseointegration.
  • Küçük Resim Yok
    Öğe
    Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial
    (Mdpi, 2021) Erelel, Mustafa; Kaskal, Mert; Akbal-Dagistan, Ozlem; Issever, Halim; Dagistanli, Ahmet Serhan; Balkanci, Hilal; Oguz, Merve Sinem
    In COVID-19-induced acute respiratory distress syndrome, the lungs are incapable of filling with sufficient air, leading to hypoxemia that results in high mortality among hospitalized patients. In clinical trials, low-molecular-weight heparin was administered via a specially designed soft-mist inhaler device in an investigator initiated, single-center, open-label, phase-IIb clinical trial. Patients with evidently worse clinical presentations were classed as the Device Group ; 40 patients were given low-molecular-weight heparin via a soft mist inhaler at a dose of 4000 IU per administration, twice a day. The Control Group, also made up of 40 patients, received the standard therapy. The predetermined severity of hypoxemia and the peripheral oxygen saturation of patients were measured on the 1st and 10th days of treatment. The improvement was particularly striking in cases of severe hypoxemia. In the 10-day treatment, low-molecular-weight heparin was shown to significantly improve breathing capability when delivered via a soft-mist inhaler.